Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Endocrine
Erschienen in: Endocrine 3/2008

01.06.2008 | Original Paper

Augmentation of estrogen receptor-mediated transcription by steroid and xenobiotic receptor

verfasst von: Nana Rokutanda, Toshiharu Iwasaki, Hiroki Odawara, Rin Nagaoka, Wataru Miyazaki, Akira Takeshita, Yukio Koibuchi, Jun Horiguchi, Noriaki Shimokawa, Yuichi Iino, Yasuo Morishita, Noriyuki Koibuchi

Erschienen in: Endocrine | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

The estrogen receptor (ER) is a key regulator of proliferation and differentiation in breast cancer cells. In the present study, the effect of steroid and xenobiotic receptor (SXR) on 17β-estradiol (E2)-induced transcription through ERα was studied. SXR augmented ER-mediated transcription in the presence of E2 in MCF-7 breast cancer-derived cells and CV-1 fibroblast-derived cells. On the other hand, SXR alone did not affect the estrogen response element (ERE)-containing promoter activity in CV-1 cells. SXR did not directly bind to ERα or ERE in vitro, indicating that SXR may affect ER-mediated transcription by altering cofactor binding to ER. Although SXR did not alter the binding between ERα and p300/CBP interacting protein (p/CIP), it decreased the binding of a specific corepressor, silencing mediator of retinoid and thyroid hormone receptors (SMRT) to liganded ERα as assessed by mammalian two-hybrid, glutathione S-transferase pull-down, immunoprecipitation and newly developed Liquid Chemiluminescent DNA Pull-Down Assays. These results indicate that SXR augmented ER-mediated transcription by dissociating SMRT from ERα. Thus, the expression of SXR in breast cancer cells may alter the ER signaling, which may play crucial role for growth and differentiation of breast cancer cells.
Literatur
1.
K.M. Dobrzycka, S.M. Townson, S. Jiang, S. Oesterreich, Estrogen receptor corepressors—a role in human breast cancer? Endocr. Relat. Cancer 10, 517–536 (2003)CrossRefPubMed
2.
3.
W. Shao, M. Brown, Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res. 6, 39–52 (2004)CrossRefPubMed
4.
K. Paech, P. Webb, G. Kuiper, S. Nilsson, J.-A. Gustafsson, P.J. Kushner, T.S. Scanlan, Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277, 1508–1510 (1997)CrossRefPubMed
5.
B.S. Katzenellenbogen, J.A. Katzenellenbogen, Estrogen receptor transcription and transactivation: estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res. 2, 335–344 (2000)CrossRefPubMed
6.
N. Albermann, F.H. Schmitz-Winnenthal, K. Z’graggen, C. Volk, M.M. Hoffmann, W.E. Haefeli, J. Weiss, Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem. Pharmacol. 70, 949–958 (2005)CrossRefPubMed
7.
G. Bertilsson, J. Heidrich, K. Svensson, M. Asman, L. Jendeberg, M. Sydow-Backman, R. Ohlsson, H. Postlind, P. Blomquist, A. Berkenstam, Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. USA 95, 12208–13122 (1998)CrossRefPubMed
8.
B. Blumberg, W. Sabbagh Jr., H. Juguilon, J. Bolado Jr., C.M. van Meter, E.S. Ong, R.M. Evans, SXR, a novel steroid and xenobiotic-18 sensing nuclear receptor. Genes Dev. 12, 3195–3205 (1998)CrossRefPubMed
9.
C.D. Klaassen, A.L. Slitt, Regulation of hepatic transporters by xenobiotic receptors. Curr. Drug Metab. 6, 309–328 (2005)CrossRefPubMed
10.
S.A. Kliewer, J.T. Moore, L. Wade, J.L. Staudinger, M.A. Watson, S.A. Jones, D.D. McKee, B.B. Oliver, T.M. Willson, R.H. Zetterstrom, T. Perlmann, J.M. Lehmann, An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92, 73–82 (1998)CrossRefPubMed
11.
J.M. Lehmann, D.D. McKee, M.A. Watson, T. Willson, J.T. Moore, S.A. Kliewer, The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102, 1016–1023 (1998)CrossRefPubMed
12.
J. Sugatani, S. Nishitani, K. Yamakawa, K. Yoshinari, T. Sueyoshi, M. Negishi, M. Miwa, Transcriptional regulation of human UGT1A1 gene expression: activated glucocorticoid receptor enhances constitutive androstane receptor/pregnane X receptor-mediated UDP-glucuronosyltransferase 1A1 regulation with glucocorticoid receptor-interacting protein 1. Mol. Pharmacol. 67, 845–855 (2005)CrossRefPubMed
13.
H. Dotzlaw, E. Leygue, P. Watson, L.C. Murphy, The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. Clin. Cancer Res. 5, 2103–2107 (1999)PubMed
14.
Y. Miki, T. Suzuki, K. Kitada, N. Yabuki, R. Shibuya, T. Moriya, T. Ishida, N. Ohuchi, B. Blumberg, H. Sasano, Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res. 66, 535–542 (2006)CrossRefPubMed
15.
R. Huang, D.J. Murry, D. Kolwankar, S.D. Hall, D.R. Foster, Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem. Pharmacol. 71, 1695–1704 (2006)CrossRefPubMed
16.
H. Masuyama, N. Suwaki, Y. Tateishi, H. Nakatsukasa, T. Segawa, Y. Hiramatsu, The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol. Endocrinol. 19, 1170–1180 (2005)CrossRefPubMed
17.
D.J. Waxman, P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys. 369, 11–23 (1999)CrossRefPubMed
18.
R.E. Watkins, G.B. Wisely, L.B. Moore, J.L. Collins, M.H. Lambert, S.P. Williams, T.M. Willson, S.A. Kliewer, M.R. Redinbo, The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292, 2329–2333 (2001)CrossRefPubMed
19.
C.K. Glass, J.M. Holloway, O.V. Devary, M.G. Rosenfeld, The thyroid hormone receptor binds with opposite transcriptional effects to a common sequence motif in thyroid hormone and estrogen response elements. Cell 54, 313–323 (1988)CrossRefPubMed
20.
C.M. Klinge, D.L. Bodenner, D. Desai, R.M. Niles, A.M. Traish, Binding of type II nuclear receptors and estrogen receptor to full and half-site estrogen response elements in vitro. Nucleic Acids Res. 25, 1903–1912 (1997)CrossRefPubMed
21.
C.M. Klinge, Estrogen receptor interaction with co-activators and co-repressors. Steroids 65, 227–251 (2000)CrossRefPubMed
22.
S.B. Nunez, J.A. Medin, O. Braissant, L. Kemp, W. Wahli, K. Ozato, J. Segars, Retinoid X receptor and peroxisome proliferator-activated receptor activate an estrogen responsive gene independent of the estrogen receptor. Mol. Cell. Endocrinol. 127, 27–40 (1997)CrossRefPubMed
23.
Y.S. Zhu, P.M. Yen, W.W. Chin, D.W. Pfaff, Estrogen and thyroid hormone interaction on regulation of gene expression. Proc. Natl. Acad. Sci. USA 93, 12587–12592 (1996)CrossRefPubMed
24.
T.V. Beischlag, G.H. Perdew, ERα-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription. J. Biol. Chem. 280, 21607–21611 (2005)CrossRefPubMed
25.
R. Duan, W. Porter, I. Samudio, C. Vyhlidal, M. Kladde, S. Safe, Transcriptional activation of c-fos protooncogene by 17β-estradiol: mechanism of aryl hydrocarbon receptor-mediated inhibition. Mol. Endocrinol. 13, 1511–1521 (1999)CrossRefPubMed
26.
M.S. Ricci, D.G. Toscano, C.J. Mattingly, W.A. Toscano Jr., Estrogen receptor reduces CYP1A1 induction in cultured human endometrial cells. J. Biol. Chem. 274, 3430–3438 (1999)CrossRefPubMed
27.
W.L. Kraus, K.E. Weis, B.S. Katzenellenbogen, Inhibitory cross-talk between steroid hormone receptors: differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist- and antagonist-occupied progestin receptors. Mol. Cell. Biol. 15, 1847–1857 (1995)PubMed
28.
C.L. Smith, Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol. Reprod. 58, 627–632 (1998)CrossRefPubMed
29.
C. Carlberg, T.W. Dunlop, An integrated biological approach to nuclear receptor signaling in physiological control and disease. Crit. Rev. Eukaryot. Gene Expr. 16, 1–22 (2006)PubMed
30.
A.J. Horlein, A.M. Naar, T. Heinzel, J. Torchia, B. Gloss, R. Kurokawa, A. Ryan, Y. Kamei, M. Soderstrom, C.K. Glass, M.G. Rosenfeld, Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377, 397–404 (1995)CrossRefPubMed
31.
J.D. Chen, R.M. Evans, A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377, 454–457 (1995)CrossRefPubMed
32.
C.L. Smith, Z. Nawaz, B.W. O’Malley, Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol. Endocrinol. 11, 657–666 (1997)CrossRefPubMed
33.
X. Zhang, M. Jeyakumar, S. Petukhov, M.K. Bagchi, A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol. Endocrinol. 12, 513–524 (1998)CrossRefPubMed
34.
A. Takeshita, M. Taguchi, N. Koibuchi, Y. Ozawa, Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J. Biol. Chem. 277, 32453–32458 (2002)CrossRefPubMed
35.
R. Kumar, A.E. Gururaj, R.K. Vadlamudi, S.K. Rayala, The clinical relevance of steroid hormone receptor corepressors. Clin. Cancer Res. 11, 2822–2831 (2005)CrossRefPubMed
36.
J. Kurebayashi, T. Otsuki, H. Kunisue, K. Tanaka, S. Yamamoto, H. Sonoo, Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin. Cancer Res. 6, 512–518 (2000)PubMed
37.
D.R. Johnson, C.W. Li, L.Y. Chen, J.C. Ghosh, J.D. Chen, Regulation and binding of pregnane X receptor by nuclear receptor corepressor silencing mediator of retinoid and thyroid hormone receptors (SMRT). Mol. Pharmacol. 69, 99–108 (2006)PubMed
38.
L.B. Moore, D.J. Parks, S.A. Jones, R.K. Bledsoe, T.G. Consler, J.B. Stimmel, B. Goodwin, C. Liddle, S.G. Blanchard, T.M. Willson, J.L. Collins, S.A. Kliewer, Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 275, 15122–15127 (2000)CrossRefPubMed
39.
F.J. Fleming, A.D. Hill, E.W. McDermott, N.J. O’Higgins, L.S. Young, Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer. J. Clin. Endocrinol. Metab. 89, 375–383 (2004)CrossRefPubMed
40.
R.M. Lavinsky, K. Jepsen, T. Heinzel, J. Torchia, T.M. Mullen, R. Schiff, A.L. Del-Rio, M. Ricote, S. Ngo, J. Gemsch, S.G. Hilsenbeck, C.K. Osborne, C.K. Glass, M.G. Rosenfeld, D.W. Rose, Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc. Natl. Acad. Sci. USA 95, 2920–2925 (1998)CrossRefPubMed
41.
Y. Shang, X. Hu, J. DiRenzo, M.A. Lazar, M. Brown, Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103, 843–852 (2000)CrossRefPubMed
42.
Y. Shang, M. Brown, Molecular determinants for the tissue specificity of SERMs. Science 295, 2465–2468 (2002)CrossRefPubMed
43.
P. Webb, P. Nguyen, P.J. Kushner, Differential SERM effects on corepressor binding dictate ERα activity in vivo. J. Biol. Chem. 278, 6912–6920 (2003)CrossRefPubMed
44.
G. Min, H. Kim, Y. Bae, L. Petz, J.K. Kemper, Inhibitory cross-talk between estrogen receptor (ER) and constitutively activated androstane receptor (CAR). CAR inhibits ER-mediated signaling pathway by squelching p160 coactivators. J. Biol. Chem. 277, 34626–34633 (2002)CrossRefPubMed
45.
E.K. Keeton, M. Brown, Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol. Endocrinol. 19, 1543–1554 (2005)CrossRefPubMed
46.
R. Nagaoka, T. Iwasaki, N. Rokutanda, A. Takeshita, Y. Koibuchi, J. Horiguchi, N. Shimokawa, Y. Iino, Y. Morishita, N. Koibuchi, Tamoxifen activates CYP3A4 and MDR-1genes through steroid and xenobiotic receptor in breast cancer cells. Endocrine 30, 261–268 (2006)CrossRefPubMed
47.
T. Iwasaki, W.W. Chin, L. Ko, Identification and characterization of RRM-containing coactivator activator (CoAA) as TRBP-interacting protein, and its splice variant as a coactivator modulator (CoAM). J. Biol. Chem. 276, 33375–33383 (2001)CrossRefPubMed
48.
R.N. Cohen, A. Putney, F.E. Wondisford, A.N. Hollenberg, The nuclear hormone receptors recognize distinct nuclear receptor complex. Mol. Endocrinol. 14, 900–914 (2000)CrossRefPubMed
49.
R.N. Cohen, S. Brzostek, B. Kim, M. Chorev, F.E. Wondisford, A.N. Hollenberg, The specificity of interactions between nuclear hormone receptors and corepressors is mediated by distinct amino acid sequences within the interacting domains. Mol. Endocrinol. 15, 1049–1061 (2001)CrossRefPubMed
50.
A. Takeshita, N. Koibuchi, J. Oka, M. Taguchi, Y. Shishiba, Y. Ozawa, Bisphenol-A, an 19 environmental estrogen, activates the human orphan nuclear receptor, steroid and xenobiotic receptor-mediated transcription. Eur. J. Endocrinol. 145, 513–517 (2001)CrossRefPubMed
51.
B. Goodwin, E. Hodgson, C. Liddle, The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56, 1329–1339 (1999)PubMed
52.
A. Takeshita, P.M. Yen, M. Ikeda, G.R. Cardona, Y. Liu, N. Koibuchi, E.R. Norwitz, W.W. Chin, Thyroid hormone response elements differentially modulate the interactions of thyroid hormone receptors with two receptor binding domains in the steroid receptor coactivator-1. J. Biol. Chem. 273, 21554–21562 (1998)CrossRefPubMed
53.
D. Ron, H. Dressler, pGSTag—a versatile bacterial expression plasmid for enzymatic labeling of recombinant proteins. BioTechniques 13, 866–869 (1992)PubMed
54.
W. Miyazaki, T. Iwasaki, A. Takeshita, Y. Kuroda, N. Koibuchi, Polychlorinated biphenyls suppress thyroid hormone receptor-mediated transcription through a novel mechanism. J. Biol. Chem. 279, 18195–18202 (2004)CrossRefPubMed
55.
T. Satoh, M. Yamada, T. Iwasaki, M. Mori, Negative regulation of the gene for the preprothyrotropin-releasing hormone from the mouse by thyroid hormone requires additional factors in conjunction with thyroid hormone receptors. J. Biol. Chem. 271, 27919–27926 (1996)CrossRefPubMed
Metadaten
Titel
Augmentation of estrogen receptor-mediated transcription by steroid and xenobiotic receptor
verfasst von
Nana Rokutanda
Toshiharu Iwasaki
Hiroki Odawara
Rin Nagaoka
Wataru Miyazaki
Akira Takeshita
Yukio Koibuchi
Jun Horiguchi
Noriaki Shimokawa
Yuichi Iino
Yasuo Morishita
Noriyuki Koibuchi
Publikationsdatum
01.06.2008
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2008
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-008-9091-9

Weitere Artikel der Ausgabe 3/2008

Endocrine 3/2008 Zur Ausgabe

Original Paper

Growth hormone (GH) secretion, GH-dependent gene expression, and sexually dimorphic body growth in young rats with chronic renal failure

Original Paper

Cyclooxygenases expression and distribution in the normal ovary and their role in ovarian cancer in the domestic hen (Gallus domesticus)

Original Paper

Interleukin-6 stimulates lipolysis in porcine adipocytes

Original Paper

Clinical and epidemiological characteristics of thyroid hemiagenesis: ultrasound screening in patients with thyroid disease and normal population

Original Paper

Calcitonin induces expression of the inducible cAMP early repressor in osteoclasts

Original Paper

Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise